A pair of drugmakers and the FDA found themselves in the news lately, but it’s safe to say it wasn’t for the reasons they would prefer. Both situations stress the importance of data needed to secure product approvals, and, perhaps, payer and provider uptake.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.